Therapy for type 2 diabetes: Where do we stand after the UK prospective diabetes study?

European Journal of Endocrinology

Volumn 140, Issue 1, 1999, Pages 4-6

  Lopez Liuchi, José V ^a   Meier, Christoph A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CAPTOPRIL; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC OBESITY; DIET THERAPY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIET THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PHENFORMIN; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; TOLBUTAMIDE;

EID: 0033049216     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1400004     Document Type: Review

References (11)

1. DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. New England Journal of Medicine 1993 329 977-986.
2. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970 19 (Suppl 2) 747-850.
3. Leibowititz G & Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 1996 39 503-514.
4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice 1995 28 103-117.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 837-853.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 854-865.
7. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 1998 317 703-713
8. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. British Medical Journal 1998 317 713-720.
9. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance. Diabetologia 1991 34 877-890.
10. Vischer UM. Hyperglycemia and the pathogenesis of atherosclerosis: lessons from murine models. European Journal of Endocrinology 1999 140 1-3.
11. Charles M, Morange P, Eschewege E, Andre P, Vague P & Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese non-diabetic subjects: the BIGPRO1 Study. Biguanides and the prevention of the risk of obesity. Diabetes Care 1998 21 1967-1972.